GERMANY – 2026/01/08: In this photo illustration, the Humana Inc. logo seen displayed on a smartphone. (Photo Illustration by Igor Golovniov/SOPA Images/LightRocket via Getty Images)
SOPA Images/LightRocket via Getty Images
Humana stock plummeted 21% on January 27. Humana is a “pure play” on Medicare Advantage—around 85% of their operations. Following CMS’s announcement of a 0.09% rate increase for 2027, HUM experienced greater losses than any other company. Humana ranks as the second-largest MA provider (17% national enrollment, 8.5 million members) with virtually no cushion from diversification. Additionally, see – What Just Happened With UnitedHealth Stock?
Humana has not yet disclosed its Q4 2025 results (scheduled for February 11), but Q3 2025 revealed a decline:
- Q3 revenue: $32.65 billion (up 11% YoY)
- Q3 adjusted EPS: $3.24 (down 22% YoY)
- Medical benefit ratio: 91.1% in Q3 2025
That 91.1% benefit ratio is harsh. For context, anything above 90% offers very scant opportunities for profitability. Humana anticipates full-year 2025 adjusted EPS to be around $17.00, with a projected benefit ratio of 90.1-90.5%.
There’s also the issue with membership—they are losing customers. Humana predicts a decline in Medicare Advantage membership of about 425,000 members in 2025. Why is this happening? They are withdrawing from unprofitable markets and counties where the economics are unfavorable.
If you invested in Humana a year ago, nearly one-third of your investment has already evaporated. This serves to illustrate why diversified portfolios are more effective. If you are looking for potential upside with less volatility than owning an individual stock like HUM, consider the High Quality Portfolio. It has consistently outperformed its benchmark—a mix of the S&P 500, Russell, and S&P MidCap indexes—achieving over 105% returns since its inception. Why is this the case? As a collective, HQ Portfolio stocks have yielded superior returns with lower risks compared to the benchmark index; it’s shown less volatility, as detailed in HQ Portfolio performance metrics.
What about their Star Ratings disaster?
This is crucial. Humana’s Star Ratings—which determine bonus payments from CMS—plummeted for the bonus year 2027. Reduced star ratings result in lower reimbursement and diminished capacity to provide attractive benefits to draw in members. Management has stated they are aiming for top-quartile Stars by the bonus year 2028, but that is over two years away. In the interim, they are at a competitive disadvantage compared to UNH and others with superior ratings.
Valuation—is this a value trap?
At around $209 per share (following yesterday’s 21% decline), HUM is trading at approximately 13x estimated 2026 EPS. Also, take a look at Humana Valuation Ratios Comparison. The valuation appears slightly cheap compared to historical multiples of 16-18x, but there is a reason for this:
- The company is anticipating 2025 adjusted EPS of $17.00
- Q4 2025 analyst forecasts: Loss of $4.00 per share (in contrast to a loss of $2.16 in Q4 2024)
- The Q4 loss projection accounts for investments aimed at rectifying their Star Ratings issue, yet it highlights the intensity of the turnaround challenge.
Can they get through this? Humana possesses structural advantages in CenterWell (their care delivery division) and is focusing on operational efficiencies (aiming for over $100M in savings via AI and outsourcing). Nevertheless, the 2027 rate proposal is critical for a pure-play MA company. Should the 0.09% rate remain unchanged, Humana will need to:
- Significantly raise the maximum out-of-pocket limits
- Eliminate supplemental benefits (dental, vision, gym memberships)
- Exit additional unprofitable markets
- Potentially decrease provider payment rates
Industry lobbyists (Better Medicare Alliance) are contesting the proposed rates, and the final announcement in April could be more favorable. However, relying on regulatory relief is precarious.
Also, check out – What’s Behind The Crash In CVS Stock?
The verdict—recovery story or falling knife?
Humana at $209 reflects significant distress. The demographic advantage (aging population) underpins long-term demand for Medicare Advantage, yet the economics have fundamentally transformed. Management’s “reset” strategy for 2025-2026 has yet to demonstrate its effectiveness, and now they confront additional regulatory challenges.
Investment view: This is a show-me story. Until we are privy to Q4 results (Feb 11), final 2027 rates (April), and evidence that the benefit ratio can decrease back below 89%, HUM poses too much risk for most investors. The 35% analyst upside projection appears optimistic given the structural hurdles. If you believe the 2027 rates will be adjusted upward in April and that Humana can successfully implement its turnaround, there’s asymmetric upside—but that remains a significant “if.”
Moreover, investing in an individual stock without thorough analysis can be risky. Consider the Trefis Reinforced Value (RV) Portfolio, which has outperformed its all-cap stocks benchmark (a combination of the S&P 500, S&P mid-cap, and Russell 2000 benchmark indices) and provided strong returns for investors. Why is this? The quarterly rebalanced mix of large-, mid-, and small-cap RV Portfolio stocks has offered a responsive approach to capitalizing on positive market conditions while mitigating losses in bearish markets, as elaborated in RV Portfolio performance metrics.